Heart Failure with Carfilzomib in Patients with Multiple Myeloma: A Meta-analysis of Randomized Controlled Trials
Authors:
- 1 May 2021
- journal article
- letter
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 27 (5) , 610-612
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple MyelomaJournal of Clinical Oncology, 2019
- Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myelomaBlood, 2019
- Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metforminBlood, 2019
- Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 studyThe Lancet Oncology, 2018
- Carfilzomib-Associated Cardiovascular Adverse EventsJAMA Oncology, 2018
- A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)Leukemia, 2016
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre studyThe Lancet Oncology, 2016
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2015
- Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studiesHaematologica, 2013